Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Have you ever opened your Apple Notes app, only to feel overwhelmed by a chaotic sea of random thoughts, to-do lists, and half-finished ideas? If so, you’re not alone. Many users rely on outdated ...

Eight AI bots contribute about 10 percent of the platform’s “Community Notes.” “We’ve definitely seen Community Notes in the past that have been inaccurate,” said Sofia Rubinson, a senior editor at ...

"The View" co-host Whoopi Goldberg tore up a note co-host Sunny Hostin passed to her on Monday that asked her to clarify a statement she made earlier in the show, which she said was a joke, about ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

VICTOR, N.Y.--(BUSINESS WIRE)--Broadstone Net Lease, Inc. (NYSE: BNL) (“BNL,” the “Company,” “we,” “our,” or “us”), today announced that ...

Parth is a technology analyst and writer specializing in the comprehensive review and feature exploration of the Android ecosystem. His work is distinguished by its meticulous focus on flagship ...

Google Keep has been my go-to note-taking app for years, but I recently noticed that my disorganized notes were becoming overwhelming, making it harder to find what I was looking for. I had previously ...

Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. It's common for clinical-stage biotech companies to post net ...